(Q38698579)

5 September 2017

title

Treatment of muscle-invasive bladder cancer: A systematic review (English)

1 reference

5 September 2017

1 reference

1 reference

1

Roger Chou

1 reference

5 September 2017

Shelley S Selph

2

1 reference

5 September 2017

David I Buckley

3

1 reference

5 September 2017

Katie S Gustafson

4

1 reference

5 September 2017

Jessica C Griffin

5

1 reference

5 September 2017

Sara E Grusing

6

1 reference

5 September 2017

John L Gore

7

1 reference

5 September 2017

language of work or name

English

0 references

publication date

15 January 2016

1 reference

5 September 2017

number of pages

10

1 reference

inferred from page(s)

published in

Cancer

1 reference

5 September 2017

volume

122

1 reference

5 September 2017

issue

6

1 reference

5 September 2017

page(s)

842-851

1 reference

5 September 2017

cites work

Cancer statistics, 2014

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29843

Radical cystectomy versus bladder-preserving therapy for muscle-invasive urothelial carcinoma: examining confounding and misclassification biasin cancer observational comparative effectiveness research.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29843

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29843

Survival after bladder-preservation with brachytherapy versus radical cystectomy; a single institution experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29843

Extent of pelvic lymphadenectomy and its impact on outcome in patients diagnosed with bladder cancer: analysis of data from the Surveillance, Epidemiology and End Results Program data base

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29843

The number of nodes removed as well as the template of the dissection is independently correlated to cancer-specific survival after radical cystectomy for muscle-invasive bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29843

Super extended versus extended pelvic lymph node dissection in patients undergoing radical cystectomy for bladder cancer: a comparative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29843

Stage-specific impact of extended versus standard pelvic lymph node dissection in radical cystectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29843

Surgical factors influence bladder cancer outcomes: a cooperative group report

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29843

Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29843

Neoadjuvant chemotherapy with cisplatin and methotrexate in patients with muscle-invasive bladder tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29843

International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29843

Neoadjuvant chemotherapy with gemcitabine/cisplatin vs. methotrexate/vinblastine/doxorubicin/cisplatin for muscle-invasive urothelial carcinoma of the bladder: a retrospective analysis from the University of Southern California

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29843

Retrospective analysis of clinical outcomes with neoadjuvant cisplatin-based regimens for muscle-invasive bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29843

Relative efficacy of perioperative gemcitabine and cisplatin versus methotrexate, vinblastine, adriamycin, and cisplatin in the management of locally advanced urothelial carcinoma of the bladder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29843

Adjuvant chemotherapy with cisplatin and gemcitabine versus chemotherapy at relapse in patients with muscle-invasive bladder cancer submitted to radical cystectomy: an Italian, multicenter, randomized phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29843

A comparison of the outcomes of neoadjuvant and adjuvant chemotherapy for clinical T2-T4aN0-N2M0 bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29843

Comparison between neoadjuvant and adjuvant gemcitabine plus cisplatin chemotherapy for muscle-invasive bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29843

Trimodality therapy for bladder conservation in treatment of invasive bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29843

ICUD-EAU International Consultation on Bladder Cancer 2012: Radical cystectomy and bladder preservation for muscle-invasive urothelial carcinoma of the bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29843

The impact of the extent of lymphadenectomy on oncologic outcomes in patients undergoing radical cystectomy for bladder cancer: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29843

Extent of lymph node dissection and recurrence-free survival after radical cystectomy: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29843

Cisplatin nephrotoxicity: mechanisms and renoprotective strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29843

Asymmetric funnel plots and publication bias in meta-analyses of diagnostic accuracy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29843

The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29843

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29843

Lymphadenectomy for bladder cancer at the time of radical cystectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29843

A systematic review of neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29843

Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29843

Radiotherapy with or without Chemotherapy in Muscle-Invasive Bladder Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29843

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29843

7 January 2021

Transurethral resection of muscle-invasive bladder cancer: 10-year outcome

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29843

7 January 2021

Effects of age and comorbidity on treatment and survival of patients with muscle-invasive bladder cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29843

7 January 2021

Bladder preservation in selected patients with muscle-invasive bladder cancer by complete transurethral resection of the bladder plus systemic chemotherapy: long-term follow-up of a phase 2 nonrandomized comparative trial with radical cystectomy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29843

7 January 2021

Stage-specific impact of pelvic lymph node dissection on survival in patients with non-metastatic bladder cancer treated with radical cystectomy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29843

7 January 2021

Does extended lymphadenectomy increase the morbidity of radical cystectomy?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29843

7 January 2021

Outcome after radical cystectomy with limited or extended pelvic lymph node dissection

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29843

7 January 2021

Lymphadenectomy in patients with transitional cell carcinoma of the urinary bladder; significance for staging and prognosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29843

7 January 2021

Role of pelvic lymph node dissection in lymph node-negative patients with invasive bladder cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29843

7 January 2021

Randomised phase III study of neoadjuvant chemotherapy with methotrexate, doxorubicin, vinblastine and cisplatin followed by radical cystectomy compared with radical cystectomy alone for muscle-invasive bladder cancer: Japan Clinical Oncology Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29843

7 January 2021

Neoadjuvant cisplatin-methotrexate chemotherapy for invasive bladder cancer -- Nordic cystectomy trial 2

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29843

7 January 2021

Five-year followup of a prospective trial of radical cystectomy and neoadjuvant chemotherapy: Nordic Cystectomy Trial I. The Nordic Cooperative Bladder Cancer Study Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29843

7 January 2021

Neoadjuvant chemotherapy in bladder cancer: a randomized study. Nordic Cystectomy Trial I

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29843

7 January 2021

The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: a prospective comparative trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29843

7 January 2021

Integrated therapy for locally advanced bladder cancer: final report of a randomized trial of cystectomy plus adjuvant M-VAC versus cystectomy with both preoperative and postoperative M-VAC

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29843

7 January 2021

Standard or extended lymphadenectomy in radical cystectomy: what metric of surgical quality for lymph node dissections matters in improving patient outcomes?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29843

7 January 2021

Neoadjuvant Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin With Pegfilgrastim Support in Muscle-Invasive Urothelial Cancer: Pathologic, Radiologic, and Biomarker Correlates

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29843

7 January 2021

Identifiers

DOI

10.1002/CNCR.29843

1 reference

5 September 2017

1 reference